Trv Gp Vi LLC Purchases New Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX)

TRV GP VI LLC purchased a new stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 194,174 shares of the company's stock, valued at approximately $600,000. Tango Therapeutics accounts for approximately 0.5% of TRV GP VI LLC's investment portfolio, making the stock its 4th largest position. TRV GP VI LLC owned 0.18% of Tango Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. State Street Corp increased its stake in shares of Tango Therapeutics by 26.8% in the third quarter. State Street Corp now owns 2,318,208 shares of the company's stock worth $17,850,000 after purchasing an additional 489,949 shares in the last quarter. Barclays PLC boosted its holdings in Tango Therapeutics by 78.3% in the 3rd quarter. Barclays PLC now owns 126,281 shares of the company's stock worth $972,000 after buying an additional 55,470 shares during the period. Geode Capital Management LLC increased its stake in Tango Therapeutics by 11.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company's stock worth $10,538,000 after buying an additional 142,710 shares in the last quarter. Catalina Capital Group LLC bought a new stake in Tango Therapeutics during the fourth quarter valued at about $82,000. Finally, Congress Asset Management Co. lifted its position in shares of Tango Therapeutics by 9.0% in the fourth quarter. Congress Asset Management Co. now owns 227,989 shares of the company's stock valued at $704,000 after acquiring an additional 18,919 shares in the last quarter. Hedge funds and other institutional investors own 78.99% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "buy" rating and set a $13.00 target price on shares of Tango Therapeutics in a research report on Monday, April 14th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tango Therapeutics presently has a consensus rating of "Buy" and an average target price of $12.33.

Insider Buying and Selling at Tango Therapeutics

In related news, CEO Barbara Weber sold 9,778 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total value of $29,236.22. Following the completion of the transaction, the chief executive officer now owns 1,631,264 shares of the company's stock, valued at approximately $4,877,479.36. This trade represents a 0.60 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 24,268 shares of company stock worth $72,561 over the last 90 days. 6.30% of the stock is owned by insiders.

Tango Therapeutics Price Performance

Shares of TNGX stock traded down $0.01 during trading hours on Thursday, hitting $1.46. The stock had a trading volume of 461,699 shares, compared to its average volume of 1,073,209. The stock's 50-day moving average price is $1.73 and its two-hundred day moving average price is $3.18. Tango Therapeutics, Inc. has a one year low of $1.11 and a one year high of $12.02. The stock has a market capitalization of $157.84 million, a price-to-earnings ratio of -1.24 and a beta of 1.03.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The firm had revenue of $4.12 million for the quarter, compared to analysts' expectations of $7.84 million. As a group, equities research analysts predict that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.